Shares of Aarti Pharmalabs Ltd soared 8% to ₹684.55 in early trade following the company’s strong Q3 FY25 performance, driven by 40% YoY growth in net profit and improved operational metrics.
Stock Performance Update (as of 9:23 AM)
- Current share price: ₹684.55 (+8%)
- Previous close: ₹636.30
- Market cap: ₹62.76 billion
- 52-week range: ₹399.55 – ₹734.00
Key Financial Highlights (Q3 FY25)
- Sales: ₹538 crore, up 20% YoY from ₹449 crore in Q3 FY24.
- EBITDA: ₹129 crore, a 34% YoY increase from ₹95.7 crore.
- Net profit: ₹74 crore, up 40% YoY compared to ₹52.8 crore in Q3 FY24.
- EPS: ₹8.16, a 40% YoY growth from ₹5.82.
Sequential Growth Comparison (Q3 FY25 vs Q2 FY25)
- Sales: Increased from ₹458 crore in Q2 FY25 to ₹538 crore in Q3 FY25.
- EBITDA: Rose from ₹93.7 crore to ₹129 crore, highlighting improved operational efficiency.
- Net profit: Increased from ₹54.6 crore to ₹74 crore.
- EPS: Improved from ₹6.03 to ₹8.16.
The robust growth in revenue and profitability is attributed to strong demand across the company’s product segments, improved cost management, and operational efficiency. The EBITDA margin improvement reflects effective control over production costs and enhanced manufacturing efficiency.
Disclaimer:
The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Business Upturn is not liable for any losses arising from the use of this information.
